Paxman AB (PAX) - Net Assets
Based on the latest financial reports, Paxman AB (PAX) has net assets worth Skr427.76 Million SEK (≈ $46.03 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr487.65 Million ≈ $52.48 Million USD) and total liabilities (Skr59.89 Million ≈ $6.45 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PAX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr427.76 Million |
| % of Total Assets | 87.72% |
| Annual Growth Rate | 42.85% |
| 5-Year Change | 1406.05% |
| 10-Year Change | N/A |
| Growth Volatility | 350.09 |
Paxman AB - Net Assets Trend (2016–2024)
This chart illustrates how Paxman AB's net assets have evolved over time, based on quarterly financial data. Also explore PAX asset base for the complete picture of this company's asset base.
Annual Net Assets for Paxman AB (2016–2024)
The table below shows the annual net assets of Paxman AB from 2016 to 2024. For live valuation and market cap data, see PAX stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr163.99 Million ≈ $17.65 Million |
+33.75% |
| 2023-12-31 | Skr122.62 Million ≈ $13.20 Million |
+7.37% |
| 2022-12-31 | Skr114.20 Million ≈ $12.29 Million |
-9.19% |
| 2021-12-31 | Skr125.75 Million ≈ $13.53 Million |
+1054.88% |
| 2020-12-31 | Skr10.89 Million ≈ $1.17 Million |
-61.61% |
| 2019-12-31 | Skr28.36 Million ≈ $3.05 Million |
+11.68% |
| 2018-12-31 | Skr25.39 Million ≈ $2.73 Million |
-22.50% |
| 2017-12-31 | Skr32.77 Million ≈ $3.53 Million |
+246.44% |
| 2016-12-31 | Skr9.46 Million ≈ $1.02 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Paxman AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 325.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr40.20 Million | 24.51% |
| Common Stock | Skr19.01 Million | 11.59% |
| Other Components | Skr104.79 Million | 63.90% |
| Total Equity | Skr163.99 Million | 100.00% |
Paxman AB Competitors by Market Cap
The table below lists competitors of Paxman AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hwa Fong Rubber Ind Co Ltd
TW:2109
|
$126.73 Million |
|
Ditas Dogan Yedek Parca Imalat ve Teknik AS
IS:DITAS
|
$126.79 Million |
|
Cannara Biotech Inc
V:LOVE
|
$126.80 Million |
|
Megaforce Co Ltd
TWO:3294
|
$126.86 Million |
|
Her Chee Industrial Co Ltd
TWO:8937
|
$126.63 Million |
|
Dongkuk Industries Co. Ltd
KQ:005160
|
$126.58 Million |
|
Encounter Resources Ltd
AU:ENR
|
$126.57 Million |
|
Tarsons Products Limited
NSE:TARSONS
|
$126.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Paxman AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 122,616,000 to 163,994,000, a change of 41,378,000 (33.7%).
- Net income of 40,196,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 95,274,000.
- Other factors increased equity by 96,456,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr40.20 Million | +24.51% |
| Other Comprehensive Income | Skr-95.27 Million | -58.1% |
| Other Changes | Skr96.46 Million | +58.82% |
| Total Change | Skr- | 33.75% |
Book Value vs Market Value Analysis
This analysis compares Paxman AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.89x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 68.53x to 5.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Skr0.74 | Skr50.60 | x |
| 2017-12-31 | Skr2.76 | Skr50.60 | x |
| 2018-12-31 | Skr1.59 | Skr50.60 | x |
| 2019-12-31 | Skr1.76 | Skr50.60 | x |
| 2020-12-31 | Skr0.68 | Skr50.60 | x |
| 2021-12-31 | Skr7.20 | Skr50.60 | x |
| 2022-12-31 | Skr6.01 | Skr50.60 | x |
| 2023-12-31 | Skr6.43 | Skr50.60 | x |
| 2024-12-31 | Skr8.59 | Skr50.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Paxman AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 24.51%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.89%
- • Asset Turnover: 1.11x
- • Equity Multiplier: 1.39x
- Recent ROE (24.51%) is above the historical average (-19.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 24.37% | 9.30% | 1.13x | 2.33x | Skr1.36 Million |
| 2017 | -20.52% | -21.46% | 0.69x | 1.39x | Skr-10.00 Million |
| 2018 | -27.96% | -12.24% | 1.04x | 2.19x | Skr-9.64 Million |
| 2019 | 9.72% | 3.23% | 1.00x | 3.00x | Skr-80.10K |
| 2020 | -176.20% | -24.58% | 1.01x | 7.07x | Skr-20.27 Million |
| 2021 | -10.16% | -13.28% | 0.58x | 1.32x | Skr-25.35 Million |
| 2022 | -9.04% | -6.59% | 0.90x | 1.52x | Skr-21.74 Million |
| 2023 | 6.79% | 3.96% | 1.26x | 1.36x | Skr-3.93 Million |
| 2024 | 24.51% | 15.89% | 1.11x | 1.39x | Skr23.80 Million |
Industry Comparison
This section compares Paxman AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $171,567,428
- Average return on equity (ROE) among peers: -27.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Paxman AB (PAX) | Skr427.76 Million | 24.37% | 0.14x | $126.73 Million |
| Acarix A/S (ACARIX) | $15.12 Million | -127.02% | 0.21x | $33.84 Million |
| Arcoma AB (ARCOMA) | $48.66 Million | 5.27% | 0.68x | $11.55 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $387.11 Million | -0.84% | 0.62x | $61.64 Million |
| BICO Group AB (BICO) | $2.31 Million | 0.00% | 2.47x | $159.82 Million |
| Boule Diagnostics AB (BOUL) | $295.74 Million | 7.87% | 0.93x | $14.38 Million |
| CellaVision AB (CEVI) | $887.58 Million | 17.25% | 0.23x | $311.10 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $26.09 Million | -70.24% | 0.12x | $11.57 Million |
| Chordate Medical Holding AB (CMH) | $25.64 Million | -77.06% | 0.22x | $29.05K |
| C-Rad AB (publ) (CRAD-B) | $29.82 Million | -34.38% | 0.50x | $86.08 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $331.97K |
About Paxman AB
Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment worldwide. It serves various cancer centers and hospitals. The company has collaborated with the University of Huddersfield and the University of Leeds to develop a wearable medical cooling device; and the National University Hospital of … Read more